Jichun Ma is a prominent inventor based in Germantown, MD (US), known for his significant contributions to the field of cancer therapeutics. With a total of 3 patents, he has focused on developing innovative solutions for treating various types of cancer.

Latest Patents

His latest patents include groundbreaking work on binding molecules specific for claudin 18.2, which are crucial for the treatment of cancer and other diseases. These patents describe compositions and methods for making isolated binding molecules, such as antibodies or antigen-binding fragments, that are useful as therapeutics for treating and preventing diseases associated with cells expressing claudin 18.2. This includes tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and gallbladder cancer. Additionally, the patents detail pharmaceutical formulations that can be used either as single agents or in combination therapies with other anticancer agents, including immune checkpoint inhibitors.

Career Highlights

Jichun Ma is currently associated with Sparx Bioscience Limited, where he continues to advance his research and development efforts in the field of oncology. His work is characterized by a commitment to improving therapeutic options for patients suffering from various cancers.

Collaborations

Some of his notable coworkers include Guidong Zhu and Jingdong Ye, who contribute to the collaborative efforts in research and development at Sparx Bioscience Limited.

Conclusion

Jichun Ma's innovative work in cancer therapeutics highlights his dedication to addressing critical health challenges. His patents and ongoing research are paving the way for new treatment options that could significantly impact patient outcomes in oncology.